Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients

Coleman, Craig I; Pandya, Shivani; Wang, Li; Baser, Onur; Cai, Jennifer; Ingham, Mike; Bookhart, Brahim

doi:10.2217/cer-2019-0002

Cited by 10Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes Management and Research

Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients

Open access

Coleman, Craig I, Pandya, Shivani, Wang, Li, Baser, Onur, Cai, Jennifer, Ingham, Mike, Bookhart, Brahim·2019·Journal of Comparative Effectiveness Research

DOI 10.2217/cer-2019-0002

Open this paper in CoChat — free account

Abstract

Aim: Real-world effectiveness of canagliflozin 300 mg versus glucagon-like peptide-1 receptor agonists (GLP1RAs) was examined in patients with Type II diabetes. Patients & methods: Patients were selected from the Optum integrated database of administrative claims and electronic health record data (1 January 2013 to 31 March 2015). Results: Patients were less likely to discontinue (p Conclusion: Patients were less likely to discontinue or switch with canagliflozin than GLP1RA, and were more likely to add-on. Canagliflozin patients were more likely to achieve HbA1c <8.0% and weight loss ≥5% than GLP1RA patients.

Integrity signals

Registry

Crossref · 10.2217/cer-2019-0002

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The few studies that have evaluated real-world effectiveness of GLP-1 RAs have yielded inconsistent results.
“The few studies that have evaluated real-world effectiveness of GLP-1 RAs have yielded inconsistent results.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [29]

International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,369 · see citing works
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · see citing works
Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research
Austin, P. (2009) · Communications in statistics. Simulation and computation · doi:10.1080/03610910902859574 · Cited by 2,323 · see citing works
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167 · see citing works
Microvascular and Macrovascular Complications of Diabetes
Fowler, M. J. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.2.77 · Cited by 1,954 · see citing works
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · see citing works
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376 · see citing works
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979 · see citing works
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · see citing works
Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell-Jones, D. L., & Khan, R. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 556 · see citing works
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 499 · see citing works
Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D. A. H., Khunti, K., & Davies, M. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 496 · see citing works
Clinical Outcomes and Adherence to Medications Measured by Claims Data in Patients With Diabetes
Pladevall, M., Williams, L. K., Potts, L. A., Divine, G., Xi, H., & Lafata, J. E. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2800 · Cited by 404 · see citing works
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Vallon, V. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-110046 · Cited by 349 · see citing works
Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
Carls, G., Huynh, J., Tuttle, E., Yee, J., & Edelman, S. V. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0280-5 · Cited by 228 · see citing works
Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
Mearns, E. S., Sobieraj, D. M., White, C. M., Saulsberry, W. J., Kohn, C. G., Doleh, Y., Zaccaro, E., & Coleman, C. I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125879 · Cited by 142 · see citing works
Self-citation
Weight Change in Diabetes and Glycemic and Blood Pressure Control
Feldstein, A. C., Nichols, G. A., Smith, D. H., Stevens, V. J., Bachman, K. H., Rosales, A. G., & Perrin, N. (2008) · Diabetes Care · doi:10.2337/dc08-0426 · Cited by 142 · see citing works
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Lee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 79 · see citing works
Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States
Cai, J. X., Wang, Y., Başer, O., Xie, L., & Chow, W. S. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1208208 · Cited by 37 · see citing works
Self-citation
Predictors of suboptimal glycaemic control in type 2 diabetes patients: The role of medication adherence and body mass index in the relationship between glycaemia and age
Nagrebetsky, A., Griffin, S. J., Kinmonth, A. L., Sutton, S. R., Craven, A., & Farmer, A. A. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.003 · Cited by 36 · see citing works
Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States
Cai, J. X., Divino, V. M., & Burudpakdee, C. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1320277 · Cited by 35 · see citing works
Self-citation
The Impact of Weight Loss on Weight-related Quality of Life and Health Satisfaction: Results From a Trial Comparing Canagliflozin With Sitagliptin in Triple Therapy Among People With Type 2 Diabetes
Traina, S., Guthrie, R. M., & Slee, A. E. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2752 · Cited by 27 · see citing works
Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis
Buysman, E. K., Chow, W. S., Henk, H. J., & Rupnow, M. F. T. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0064-8 · Cited by 19 · see citing works
The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes
Traina, S., Slee, A. E., Woo, S., & Canovatchel, W. J. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0145-8 · Cited by 10 · see citing works
A Network Meta-Analysis (NMA) to Assess the Longer-Term Relative Efficacy of Canagliflozin in Patients with Type 2 Diabetes Inadequately Controlled on Metformin
Taieb, V., Pacou, M., Schroeder, M., Nielsen, A. T. N., Schubert, A., & Neslusan, C. A. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.2046 · Cited by 9 · see citing works
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting
Wysham, C., Pilon, D., Ingham, M., Lafeuille, M., Émond, B., Kamstra, R. L., Pfeifer, M. A., & Lefèbvre, P. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1454417 · Cited by 8 · see citing works
Self-citation
Bayesian Network Meta-Analysis (Nma) to Assess Relative Efficacy of Canagliflozin (Cana) Versus Glucagon-Like Peptide-1 (Glp-1) Agonists in Dual and Triple Therapy In Patients with type 2 Diabetes Mellitus (T2dm)
Sanden, S. V., Diels, J., Guillon, P., & Nielsen, A. T. N. (2015) · Value in Health · doi:10.1016/j.jval.2015.03.319 · Cited by 8 · see citing works
Bayesian Network Meta-Analysis (NMA) to Assess the Relative Efficacy of Canagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Insulin
Taieb, V., Pacou, M., Schroeder, M., Nielsen, A. T. N., Neslusan, C. A., & Schubert, A. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.2047 · Cited by 4 · see citing works
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
Wysham, C., Lefèbvre, P., Pilon, D., Ingham, M., Lafeuille, M., Émond, B., Kamstra, R. L., Chow, W. S., Pfeifer, M. A., & Duh, M. S. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0180-8 · Cited by 4 · see citing works
Self-citation
Abstract #290: Real-World Persistence and HBA1C Goal Attainment in Patients with Type Ii Diabetes Mellitus Initiated on Canagliflozin or a Glucagon-Like Peptide-1 Receptor Agonist
Lefèbvre, P., Pilon, D., Ingham, M., Lafeuille, M., Émond, B., Kamstra, R. L., Pfeifer, M. A., & Wysham, C. (2017) · Endocrine Practice · doi:10.1016/s1530-891x(20)44410-6 · Cited by 1 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152 · see citing works
<p>Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States</p>
Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277676 · Cited by 126 · see citing works
Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions
Roberts, M. H., & Ferguson, G. T. (2020) · PharmacoEconomics - Open · doi:10.1007/s41669-020-00221-y · Cited by 59 · see citing works
“In contrast, investigating medication-taking behaviors is uniquely suited to real-world studies, where routine follow-up and monitoring occurs [36].”
Background
Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysis
Ofori‐Asenso, R., Sahle, B. W., Chin, K. L., Mazidi, M., Ademi, Z., De Bruin, M. L., & Liew, D. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3350 · Cited by 44 · see citing works
“Two additional articles were retrieved via reference screening, resulting in 22 studies (involving 31 cohorts) being included in the review (Figure 1) (36-57).”
BackgroundResultInfluential
Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
Morieri, M. L., Avogaro, A., & Fadini, G. P. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s216054 · Cited by 26 · see citing works
Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
Shamim, M. A., Patil, A., Amin, U., Roy, T., Tiwari, K., Husain, N., Kumar, J., Chenchula, S., Rao, P. P., Ganesh, V., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15777 · Cited by 23 · see citing works
Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom
Alkabbani, W., Shah, B. R., Zongo, A., Eurich, D. T., Alsabbagh, M. W., & Gamble, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15241 · Cited by 9 · see citing works
Prescription Patterns and Associated Factors of SGLT2 Inhibitors Use Among Patients Worldwide: A Systematic Review and Meta-Analysis of Real-World Studies.
Xu, M., Li, Q., Chen, N., Zhang, X., & Zhang, W. (2025) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2025.106036 · Cited by 4 · see citing works
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Body Weight, BMI, and Body Composition in Adults With Type 2 Diabetes Mellitus: A Systematic Review
Naeem, S., Ogah, C. O., Mohammed, H., Gabra, I. M., Halawa, N., & Malasevskaia, I. A. (2024) · Cureus · doi:10.7759/cureus.72771 · Cited by 2 · see citing works
“For instance, Coleman et al. (2019) demonstrated that patients on canagliflozin achieved over 5% greater weight loss compared to those on GLP-1 receptor agonists, alongside significant reductions in HbA1c, with a higher likelihood of reaching HbA1c levels below 8.0% [15].”
Influential
From molecules to the clinic—pathophysiology of sodium-glucose cotransporter 2 inhibitors and their emerging role in urology: A comprehensive review from the European Association of Urology Section of Endourology
Talyshinskii, A., Gauhar, V., Yuen, S. K. K., Güven, S., Tokas, T., Tsaturyan, A., Enikeev, D., & Somani, B. (2026) · Asian Journal of Urology · doi:10.1016/j.ajur.2025.11.004
“Coleman et al. [29] found that patients taking 300 mg canagliflozin lost more than 5% of their body weight compared with those taking glucagon-like peptide-1 receptor agonists, a result attributed to subsequent glucosuria, leading to decreased plasma glucose levels, reduced insulin release, and…”

Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting
Wysham, C., Pilon, D., Ingham, M., Lafeuille, M., Émond, B., Kamstra, R. L., Pfeifer, M. A., & Lefèbvre, P. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1454417 · Cited by 8 · see citing works
Self-citation
Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA
Singhal, M., Tan, H., Coleman, C. I., Han, M., Nguyen, C., & Ingham, M. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000704 · Cited by 8 · see citing works
Self-citation
A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin
Blonde, L., Patel, C. A., Bookhart, B., Pfeifer, M., Chen, Y., & Wu, B. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1458709 · Cited by 11 · see citing works
Self-citation
Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)
Singhal, M., Tan, H., Coleman, C. I., Herman, W. H., Cai, J. X., HAN, M., & Ingham, M. (2018) · Diabetes · doi:10.2337/db18-1287-p · Cited by 1 · see citing works
Self-citation
Body Weight (BW) Outcomes with Canagliflozin 300 mg (CANA) vs. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s) in a Real-World (RW) Setting
Coleman, C. I., Herman, W. H., Pandya, S., Wang, L., Baser, O., Cai, J. X., & Bookhart, B. (2018) · Diabetes · doi:10.2337/db18-1291-p
Self-citation

Authors: Coleman, C. I., Pandya, S., Wang, L., Baser, O., Cai, J., Ingham, M., & Bookhart, B.
Affiliations: University of Connecticut (US)
STATinMED (United States) (US)
University of Michigan Medical School, Ann Arbor, MI 48109, USA
Janssen Scientific Affairs (United States) (US)
Corresponding author: Ingham, Mike
ORCID: Coleman, Craig I
Pandya, Shivani
Wang, Li
Cai, Jennifer
Bookhart, Brahim
Venue: Journal of Comparative Effectiveness Research
Publisher: Becaris Publishing Limited
Published: 2019-08
Volume: 8
Issue: 11
Pages: 889-905
ISSN: 2042-6305 (ISSN-L)
2042-6313
DOI: 10.2217/cer-2019-0002
OpenAlex: W2971469752
Cited by: 10
References: 30
Citations by year: 2026: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2020: 4
FWCI: 1.01
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
Locations: Journal of Comparative Effectiveness Research (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: canagliflozin, GLP-1 receptor agonists, type 2 diabetes, treatment patterns, glycemic control, HbA1c, weight loss, drug discontinuation, adjunctive therapy, real-world effectiveness, SGLT2 inhibitors
MeSH terms: Canagliflozin, Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Residence Characteristics, Retrospective Studies, Weight Loss, Databases, Factual, Racial Groups, Medication Adherence, Young Adult, Electronic Health Records

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks